HLBBF
Price
$7.21
Change
-$0.29 (-3.87%)
Updated
Sep 30 closing price
Capitalization
6.5B
Intraday BUY SELL Signals
HLN
Price
$10.86
Change
+$0.36 (+3.43%)
Updated
Feb 4, 02:49 PM (EDT)
Capitalization
46.6B
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HLBBF vs HLN

Header iconHLBBF vs HLN Comparison
Open Charts HLBBF vs HLNBanner chart's image
H. Lundbeck A/S
Price$7.21
Change-$0.29 (-3.87%)
Volume$200
Capitalization6.5B
Haleon
Price$10.86
Change+$0.36 (+3.43%)
Volume$1.1K
Capitalization46.6B
HLBBF vs HLN Comparison Chart in %
HLBBF
Daily Signal:
Gain/Loss:
HLN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
HLBBF vs. HLN commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HLBBF is a Hold and HLN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (HLBBF: $6.23 vs. HLN: $10.49)
Brand notoriety: HLBBF and HLN are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HLBBF: 192% vs. HLN: 86%
Market capitalization -- HLBBF: $6.5B vs. HLN: $46.6B
HLBBF [@Pharmaceuticals: Generic] is valued at $6.5B. HLN’s [@Pharmaceuticals: Generic] market capitalization is $46.6B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.79B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HLBBF’s FA Score shows that 0 FA rating(s) are green whileHLN’s FA Score has 1 green FA rating(s).

  • HLBBF’s FA Score: 0 green, 5 red.
  • HLN’s FA Score: 1 green, 4 red.
According to our system of comparison, HLN is a better buy in the long-term than HLBBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HLBBF’s TA Score shows that 2 TA indicator(s) are bullish while HLN’s TA Score has 6 bullish TA indicator(s).

  • HLBBF’s TA Score: 2 bullish, 5 bearish.
  • HLN’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, HLN is a better buy in the short-term than HLBBF.

Price Growth

HLBBF (@Pharmaceuticals: Generic) experienced а -8.78% price change this week, while HLN (@Pharmaceuticals: Generic) price change was +0.67% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.90%. For the same industry, the average monthly price growth was -2.44%, and the average quarterly price growth was +12.84%.

Reported Earning Dates

HLN is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-1.90% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HLN($46.6B) has a higher market cap than HLBBF($6.5B). HLN has higher P/E ratio than HLBBF: HLN (22.97) vs HLBBF (10.27). HLN YTD gains are higher at: 3.759 vs. HLBBF (-9.117). HLBBF has higher annual earnings (EBITDA): 5.64B vs. HLN (2.71B). HLBBF has more cash in the bank: 3.48B vs. HLN (676M). HLN has less debt than HLBBF: HLN (8.45B) vs HLBBF (12.4B). HLBBF has higher revenues than HLN: HLBBF (24.1B) vs HLN (11B).
HLBBFHLNHLBBF / HLN
Capitalization6.5B46.6B14%
EBITDA5.64B2.71B208%
Gain YTD-9.1173.759-243%
P/E Ratio10.2722.9745%
Revenue24.1B11B219%
Total Cash3.48B676M515%
Total Debt12.4B8.45B147%
TECHNICAL ANALYSIS
Technical Analysis
HLBBFHLN
RSI
ODDS (%)
Bullish Trend 2 days ago
50%
Bearish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
40%
Momentum
ODDS (%)
Bearish Trend 2 days ago
37%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bearish Trend 2 days ago
38%
Bullish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
32%
Bullish Trend 2 days ago
54%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
32%
Bullish Trend 2 days ago
51%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
56%
Declines
ODDS (%)
N/A
Bearish Trend 7 days ago
49%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
61%
Aroon
ODDS (%)
Bearish Trend 2 days ago
40%
Bullish Trend 2 days ago
46%
View a ticker or compare two or three
Interact to see
Advertisement
HLBBF
Daily Signal:
Gain/Loss:
HLN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRPAX6.000.12
+2.04%
PGIM Jennison Energy Infrastructure A
MPSSX16.960.09
+0.53%
BNY Mellon Small Cap Multi-Strategy M
SVAYX27.370.03
+0.11%
SEI Large Cap Value Y (SIMT)
AZNAX11.75-0.03
-0.25%
Virtus Income & Growth A
RWEBX65.66-0.42
-0.64%
American Funds Washington Mutual R2E

HLBBF and

Correlation & Price change

A.I.dvisor tells us that HLBBF and HYEX have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HLBBF and HYEX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HLBBF
1D Price
Change %
HLBBF100%
N/A
HYEX - HLBBF
21%
Poorly correlated
-9.09%
HLUBF - HLBBF
18%
Poorly correlated
N/A
HLN - HLBBF
10%
Poorly correlated
-0.66%
HLNCF - HLBBF
8%
Poorly correlated
+0.87%
EAPIF - HLBBF
0%
Poorly correlated
N/A
More

HLN and

Correlation & Price change

A.I.dvisor indicates that over the last year, HLN has been loosely correlated with HLNCF. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HLN jumps, then HLNCF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HLN
1D Price
Change %
HLN100%
-0.66%
HLNCF - HLN
49%
Loosely correlated
+0.87%
TAK - HLN
42%
Loosely correlated
-0.34%
ZTS - HLN
38%
Loosely correlated
-2.02%
PRGO - HLN
32%
Poorly correlated
-1.26%
VTRS - HLN
30%
Poorly correlated
N/A
More